These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 28711678)

  • 1. Linezolid in liver failure: exploring the value of the maximal liver function capacity (LiMAx) test in a pharmacokinetic pilot study.
    Wicha SG; Frey OR; Roehr AC; Pratschke J; Stockmann M; Alraish R; Wuensch T; Kaffarnik M
    Int J Antimicrob Agents; 2017 Oct; 50(4):557-563. PubMed ID: 28711678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver function, quantified by the LiMAx test, as a predictor for the clinical outcome of critically ill patients treated with linezolid.
    Alraish R; Wicha SG; Frey OR; Roehr AC; Pratschke J; Stockmann M; Wuensch T; Kaffarnik M
    Technol Health Care; 2022; 30(2):309-321. PubMed ID: 34180433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of linezolid in critically ill patients.
    Sazdanovic P; Jankovic SM; Kostic M; Dimitrijevic A; Stefanovic S
    Expert Opin Drug Metab Toxicol; 2016 Jun; 12(6):595-600. PubMed ID: 27020789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of augmented renal clearance on the pharmacokinetics of linezolid: Advantages of continuous infusion from a pharmacokinetic/pharmacodynamic perspective.
    Barrasa H; Soraluce A; Usón E; Sainz J; Martín A; Sánchez-Izquierdo JÁ; Maynar J; Rodríguez-Gascón A; Isla A
    Int J Infect Dis; 2020 Apr; 93():329-338. PubMed ID: 32112965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic drug management of linezolid: a missed opportunity for clinicians?
    Cattaneo D; Gervasoni C; Cozzi V; Castoldi S; Baldelli S; Clementi E
    Int J Antimicrob Agents; 2016 Dec; 48(6):728-731. PubMed ID: 27769709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics/pharmacodynamics of linezolid in sepsis patients with and without continuous renal replacement therapy.
    Ide T; Takesue Y; Ikawa K; Morikawa N; Ueda T; Takahashi Y; Nakajima K; Takeda K; Nishi S
    Int J Antimicrob Agents; 2018 May; 51(5):745-751. PubMed ID: 29425834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between plasma endothelin-1 levels and severity of septic liver failure quantified by maximal liver function capacity (LiMAx test). A prospective study.
    Kaffarnik MF; Ahmadi N; Lock JF; Wuensch T; Pratschke J; Stockmann M; Malinowski M
    PLoS One; 2017; 12(5):e0178237. PubMed ID: 28542386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill Patients.
    Minichmayr IK; Schaeftlein A; Kuti JL; Zeitlinger M; Kloft C
    Clin Pharmacokinet; 2017 Jun; 56(6):617-633. PubMed ID: 27753002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients.
    Matsumoto K; Shigemi A; Takeshita A; Watanabe E; Yokoyama Y; Ikawa K; Morikawa N; Takeda Y
    Int J Antimicrob Agents; 2014 Sep; 44(3):242-7. PubMed ID: 25108880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linezolid Dosing in Patients With Liver Cirrhosis: Standard Dosing Risk Toxicity.
    Luque S; Muñoz-Bermudez R; Echeverría-Esnal D; Sorli L; Campillo N; Martínez-Casanova J; González-Colominas E; Álvarez-Lerma F; Horcajada JP; Grau S; Roberts JA
    Ther Drug Monit; 2019 Dec; 41(6):732-739. PubMed ID: 31259884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Linezolid extracorporeal removal during haemodialysis with high cut-off membrane in critically ill patients.
    Villa G; Cassetta MI; Tofani L; Valente S; Chelazzi C; Falsini S; De Gaudio AR; Novelli A; Ronco C; Adembri C
    Int J Antimicrob Agents; 2015 Oct; 46(4):465-8. PubMed ID: 26315198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variable Linezolid Exposure in Intensive Care Unit Patients-Possible Role of Drug-Drug Interactions.
    Töpper C; Steinbach CL; Dorn C; Kratzer A; Wicha SG; Schleibinger M; Liebchen U; Kees F; Salzberger B; Kees MG
    Ther Drug Monit; 2016 Oct; 38(5):573-8. PubMed ID: 27631464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacokinetics and Dosing Considerations for the Use of Linezolid in Overweight and Obese Adult Patients.
    Cojutti P; Pai MP; Pea F
    Clin Pharmacokinet; 2018 Aug; 57(8):989-1000. PubMed ID: 29080937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetic analysis of linezolid in low body weight patients with renal dysfunction.
    Tsuji Y; Yukawa E; Hiraki Y; Matsumoto K; Mizoguchi A; Morita K; Kamimura H; Karube Y; To H
    J Clin Pharmacol; 2013 Sep; 53(9):967-73. PubMed ID: 23918457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Drug Monitoring Can Improve Linezolid Dosing Regimens in Current Clinical Practice: A Review of Linezolid Pharmacokinetics and Pharmacodynamics.
    Rao GG; Konicki R; Cattaneo D; Alffenaar JW; Marriott DJE; Neely M;
    Ther Drug Monit; 2020 Feb; 42(1):83-92. PubMed ID: 31652190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 10-Year Experience of Therapeutic Drug Monitoring (TDM) of Linezolid in a Hospital-wide Population of Patients Receiving Conventional Dosing: Is there Enough Evidence for Suggesting TDM in the Majority of Patients?
    Pea F; Cojutti PG; Baraldo M
    Basic Clin Pharmacol Toxicol; 2017 Oct; 121(4):303-308. PubMed ID: 28419737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting the prognosis in acute liver failure: results from a retrospective pilot study using the LiMAx test.
    Lock JF; Kotobi AN; Malinowski M; Schulz A; Jara M; Neuhaus P; Stockmann M
    Ann Hepatol; 2013; 12(4):556-62. PubMed ID: 23813133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population Pharmacokinetics and Dosing Optimization of Linezolid in Pediatric Patients.
    Li SC; Ye Q; Xu H; Zhang L; Wang Y
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30642929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of tigecycline in critically ill patients with liver failure defined by maximal liver function capacity test (LiMAx).
    Alraish R; Wicha SG; Frey OR; Roehr AC; Pratschke J; Stockmann M; Wuensch T; Kaffarnik M
    Ann Intensive Care; 2020 Aug; 10(1):106. PubMed ID: 32754775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of Inadequate Linezolid Concentrations after Standard Dosing in Critically Ill Patients.
    Taubert M; Zoller M; Maier B; Frechen S; Scharf C; Holdt LM; Frey L; Vogeser M; Fuhr U; Zander J
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5254-61. PubMed ID: 27324768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.